SYRS, US87184Q2066

Syros Pharmaceuticals has 68 employees: what it means for Syros Pharmaceuticals stock

Published on 10/14/2026 at 00:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Syros Pharmaceuticals lists a voluntary Nasdaq delisting and a gene-control pipeline. Its profile names 68 employees and fiscal year-end 2024.

Delisting and corporate scale

Syros Pharmaceuticals lists a voluntary Nasdaq delisting among its corporate updates.
The company profile names 68 employees and a December 2024 fiscal year-end.
Syros Pharmaceuticals stock was quoted at USD 0.0004 on October 13, 2026, in OTC trading.

SYRS, US87184Q2066, Illustration mit AI erstellt.

Syros Pharmaceuticals (ISIN US87184Q2066) lists a voluntary delisting from Nasdaq among its corporate updates, while its latest dated OTC quote was USD 0.0004 on October 13, 2026. The company profile names 68 employees and a December 2024 fiscal year-end, giving the stock a markedly different trading context from its former Nasdaq listing.

Delisting changes the trading context

The company website presents the Nasdaq delisting alongside its programs in gene-expression science and hematologic cancer research. The same page highlights a November 12, 2024 release on topline data from the SELECT-MDS-1 Phase 3 trial of tamibarotene in higher-risk myelodysplastic syndrome, linking the corporate status change with a pipeline that remains central to the business description.

MarketWatch identifies Syros Pharmaceuticals as an OTC security and classifies the company in biotechnology within health care and life sciences. Its profile also lists 68 employees and a fiscal year-end of December 2024, figures that underline the company's small operating scale.

What does the profile mean?

The numerical picture is narrow but clear: 68 employees support a biotechnology business whose public materials emphasize drug discovery and clinical development rather than commercial product sales. The company's website describes a gene-control platform designed to identify targets for small-molecule medicines, while the named SELECT-MDS-1 program dates from November 12, 2024.

The OTC quote of USD 0.0004 on October 13, 2026 places the security in a highly distressed valuation context, but it is a dated US-dollar market figure rather than a current euro reference price. MarketWatch also records the security as OTC and shows a 52-week range from USD 0.0000 to USD 0.0200 on its profile page.

OTC status sets the market frame

Syros Pharmaceuticals was last quoted at USD 0.0004 in OTC trading on October 13, 2026. The company profile, its 68-employee scale and the November 12, 2024 clinical update together point to a security whose market status and development pipeline must be assessed separately.

Market context: Market report S&P 500.